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Abstract  
Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders.  
One current challenge is to identify biomarkers of early changes that may predict the clinical 
trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in 
vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging 
advances, and how these approaches help us to understand Parkinson’s Disease and atypical 
parkinsonisms.   
 
 
Introduction  
In the last decade, the molecular imaging field has entered a new era of exploration into human 
brain diseases and has proven to be a powerful tool for investigation of the human brain which is 
characterized by highly interconnected regions and networks involved in motor, cognitive and 
behavioral functions. While several of the recent molecular imaging approaches are still under 
development and probably not yet able to provide definitive answers, they represent valuable 
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tools to improve our understanding of basic molecular mechanisms and pathophysiological 
processes underlying parkinsonian disorders. One current challenge is to identify biomarkers of 
early changes that predict at the group level progression and development of selected 
manifestations of parkinsonian disorders. On an individual level, it is unclear how helpful 
molecular imaging techniques (i.e. positron emission tomography [PET] and single-photon 
emission computed tomography [SPECT]) may help stratify risk for developing motor and 
behavioral complications. This personalized medicine approach, while still in its infancy in 
Parkinson’s and related disorders, has future potential for identifying subgroups of patients for 
targeted clinical trials of novel agents. Molecular imaging with newly developed 
radiopharmaceuticals now has increased potential to reveal underlying pathological processes 
such as changes in receptors (e.g. dopaminergic and non-dopaminergic), blood flow, metabolism, 
neuroinflammation, and abnormal protein deposition.  Furthermore, some molecular imaging 
measures may provide biomarkers of target engagement or efficacy for clinical trials. While most 
imaging studies focused on central nervous system abnormalities, a few interesting studies 
imaged peripheral organs in PD1 raising the issue of their practical value. Although most 
neuroimaging investigations focused on PD, some have addressed the atypical parkinsonisms. 
This knowledge gap certainly creates the need for new molecular imaging approaches and 
biomarkers for these atypical parkinsonian disorders still not sufficiently understood. In this 
article, we will provide an overview of high-affinity radiotracers and molecular imaging 
advances, and how these approaches have had an impact in understanding PD and atypical 
parkinsonisms.    
 
Molecular Imaging of Parkinson's disease and its progression  
What have we learned from imaging the dopaminergic system ? 
Degeneration of nigrostriatal neurons are responsible for most of the classical motor 
manifestations of early PD. The underlying pathophysiology in PD includes α-synuclein 
deposition in cytoplasmic inclusions called Lewy bodies found in residual neurons in areas such 
as the substantia nigra pars compacta (SNpc), but α-synuclein also may be deposited in 
dystrophic neurons in striatal or cortical regions (Lewy neurites). Projection neurons like 
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nigrostriatal afferents have long, poorly myelinated axons and may be particularly vulnerable; 
Lewy neurites may appear prior to cell body damage.2 
While dopamine levels (Fig. 1) cannot be measured directly using imaging, several approaches 
can be used to assess altered function of nigrostriatal dopaminergic nerve terminals (Fig. 2). The 
most widely accessible approach is the use of a marker for the dopamine transporter (DAT). 
Several positron- or photon-emitting molecules are available for use with PET or SPECT, 
respectively. These ligands have varying degrees of selectivity for the DAT over other 
monoamine reuptake transporters, and pharmacokinetic profiles differ from one tracer to another. 
This may be of some practical importance because some tracers (e.g. 123I-β-CIT; 123I-(–)-2β-
Carbomethoxy-3β-(4-iodophenyl)tropane) do not reach steady state for several hours, mandating 
patients to return for imaging the day following tracer injection, while others (11C-d-threo-
methylphenidate, 18F-fluoropropyl-β-CIT, 123I-fluoropropyl-CIT) can be imaged within 1-2 hours 
of tracer injection. An alternative approach is to label the DAT ligand with 99mTc, which is an 
isotope that is widely used in clinical nuclear medicine. Striatal DAT binding correlates with loss 
of nigrostriatal dopamine terminals but may only correlate with nigral neurons when that loss 
does not exceed 50%,3 whereas direct imaging of midbrain uptake correlates with residual nigral 
neurons,4 thus striatal DAT may not reflect disease progression beyond mild-moderate 
disease.3,5,6 Striatal or nigral uptake may therefore be a useful imaging biomarker.   
A second approach to determining the integrity of the presynaptic dopaminergic terminal is to 
study binding to the vesicular monoamine transporter type 2 (VMAT2). VMAT2 is responsible 
for packaging monoamines into their appropriate synaptic vesicles and binding is accordingly not 
specific to dopamine neurons. However, more than 90% of striatal VMAT2 binding is to 
dopaminergic nerve terminals. VMAT2 binding is typically studied with 11C-
dihydrotetrabenazine (DTBZ), which is not widely available and studies can therefore only be 
performed at a few sites. However, an F18 labeled radiotracer is now commercially available 
increasing the accessibility of these measures.  VMAT2 binding may be less subject to regulation 
than DAT binding7 but this remains controversial.8 It may have some sensitivity to vesicular 
dopamine levels, such that VMAT2 binding may be increased in the rare situation where nerve 
terminals are preserved but are depleted of dopamine.9  
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The original means of studying dopaminergic function was with the use of 6-18F-fluoro-L-dopa, 
which like levodopa, is taken up by monoaminergic neurons, decarboxylated to 
(fluoro)dopamine and, in the healthy brain, packaged in synaptic vesicles. Also analogous to 
markers for DAT and VMAT2, fluorodopa uptake declines with disease progression and weakly 
inversely correlates with clinical severity, at least for mild to moderate degrees of disease 
severity.3 However, the interpretation of fluorodopa scans is somewhat more complicated in that 
uptake reflects not only the (unidirectional) decarboxylation of fluorodopa to fluorodopamine, 
but also the egress of trapped fluorodopamine from synaptic vesicles. This can be used to 
estimate dopamine turnover, which increases with disease severity.10,11  
All of these presynaptic markers of dopaminergic function show a very similar pattern in PD, 
with asymmetric involvement of the striatum, and a rostral-caudal gradient in which the posterior 
putamen is maximally affected and the caudate nucleus least. While this rostral-caudal gradient 
is preserved throughout the course of the illness,12 the decline in dopaminergic markers over time 
is better described by an exponential rather than a linear relationship, where the majority of 
change in the putamen has taken place typically within the first 5 years, akin to post-mortem 
observations,12 which have demonstrated almost total loss of tyrosine hydroxylase 
immunoreactivity within this time.6  
Concurrent studies of multiple markers reveal that in early disease stages (Hoehn & Yahr Stage 
I), the threshold for clinical manifestations was 29-44% of normal values for DAT binding, 38-
49% for VMAT2 binding and 48-62% for fluorodopa uptake.13 The more severe involvement of 
DAT binding may in part reflect downregulation of the DAT in early disease, while lesser 
involvement of fluorodopa uptake may reflect upregulation of decarboxylase activity in 
surviving dopamine neurons and/or expression of decarboxylase by serotonergic neurons. In 
studies conducted in nonhuman primates with unilateral internal carotid infusion of different 
doses of MPTP, it was found that the loss of only 30-35% of striatal terminals in nonhuman 
primates were able to generate motor parkinsonism and perhaps, more importantly, motor 
parkinsonism correlated with the nigral cell counts rather than the terminal field measures.14 In 
these animal models, [18F]-6-fluorodopa, [11C] CFT (DAT biomarker) and 11C- DTBZ correlated 
with striatal dopamine and fiber density, a reflection of terminal field function, but interestingly 
only correlated with nigral cell number within a limited range of cell loss (less than 50%),3 as 
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mentioned also above.  In contrast, while PET measures of midbrain uptake of either VMAT2 or 
DAT correlated well throughout the full range of severity of nigrostriatal injury with stereologic 
counts of nigral dopaminergic neuronal cell bodies,4 midbrain uptake of fluorodopa did not, thus 
suggesting the midbrain measures may provide a better biomarker of severity of nigrostriatal 
injury.  Other studies as well showed evidence that serial assessments with multiple markers 
provide an effective approach to evaluate evolution of dopaminergic depletion in MPTP 
monkeys.15,16  
In a cohort of patients with sporadic PD studied longitudinally over several years, de la Fuente-
Fernandez et al.17 estimated that VMAT2 binding declined 17 years prior to disease onset, 
followed by DAT binding 13 years prior, while decline in fluorodopa uptake occurs last, only 6 
years prior to disease onset. However, while fluorodopa uptake does not decline until later, 
dopamine turnover increases relatively early, an estimated eight years prior to disease onset in 
sporadic PD,10 and years or even decades prior to the expected age of onset in patients with 
LRRK2 mutations.18 Consistent with the latter observation, imaging studies have shown evidence 
of dopaminergic dysfunction in subjects with a number of pathogenic mutations. The A53T and 
A53E mutations in the alpha-synuclein gene (SNCA) can be associated with early, relatively 
symmetrical defects in presynaptic dopaminergic function.19,20 Additionally, recessive Parkin21-23 
and PINK119 mutations appear to be mostly associated with symmetrical dopaminergic losses, 
whereas in carriers of more frequent LRRK2 and GBA mutations, the dopaminergic defect is 
practically indistinguishable from that of sporadic PD.19,24 In GBA-associated PD, the severity of 
dopaminergic dysfunction is related to the degree of glucocerebrosidase enzymatic activity 
reduction induced by the specific GBA mutation: carriers of mild mutations (e.g. N370S) overlap 
with PD non-carriers, while PD carriers of severe mutations (e.g. L444P) have a similar 
phenotype to dementia with Lewy bodies.25 
Many investigators have proposed that dopamine release may also be a valid method to evaluate 
dopaminergic functions. This can be estimated by exploiting (Fig. 2) the relatively high affinity 
of [11C]-raclopride, [11C]-(+)-PHNO, [18F]fallypride	 or	 [11C]FLB-457 for post-synaptic D2/D3 
dopaminergic receptors, such that radioligand binding is subject to competition from endogenous 
dopamine.26,27 A change in binding potential can be used to estimate dopamine release at the 
striatal ([11C]-raclopride or [11C]-(+)- PHNO) or extrastriatal level ([18F]fallypride	 or	 [11C]FLB-
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457 ) in response to medications, behavioral stimuli and brain stimulation techniques. A more 
detail descriptions of these applications are reported below in the section related to behavioral 
complications in Parkinson's disease.  
 
How imaging of non-dopaminergic changes contributed to our current knowledge ?   
A large body of evidence suggests that non–dopaminergic mechanisms may also contribute to 
the pathophysiology of PD (Fig. 3, 4).  Studies conducted with serotonergic PET tracers (Fig. 3, 
4) have shed some light on understanding the role of this neurotransmitter. A PET biomarker of 
the serotonin transporter (SERT), i.e. [11C]DASB,  has shown a non-linear, gradual loss of 
presynaptic serotonergic terminal function in the subcortical and cortical areas during PD 
progression.28,29 Subsequent reports have suggested its potential role in the pathophysiology of 
levodopa-induced dyskinesias (LIDs).30 Using [11C]DASB PET together with a series of 
[11C]raclopride PET scans, these studies demonstrated that PD patients with LIDs exhibited 
relative preserved striatal serotonergic terminals (compared to profound degeneration of 
dopaminergic terminals), possibly responsible for the synaptic dopaminergic levels, and that oral 
administration of the 5-HT1A agonist buspirone (prior to levodopa) reduced levodopa-related 
striatal synaptic dopamine increases and attenuated LIDs.30,31  Serotonergic PET imaging also 
indicated similar mechanisms underlying the development of graft-induced dyskinesias (GIDs) 
in transplanted PD patients. Studies with [11C]DASB PET together with dopaminergic 
biomarkers, i.e. [18F]fluorodopa, demonstrated serotonergic hyper-innervation and elevated 
serotonin/dopamine terminal ratio in the grafted tissue of transplanted PD patients who 
developed GIDs.32,33 GIDs were markedly attenuated by systemic administration of 5-HT1A 
agonist buspirone, which, by reducing transmitter release from serotonergic neurons, may 
suggest that dyskinesias were likely related to the serotonergic hyper-innervation.  
Phosphodiesterase 10A (PDE10A) has a key role in the regulation of dopaminergic signaling in 
striatal pathways, and in promoting neuronal survival. PDE10A is a basal ganglia expressed dual 
substrate enzyme, which regulates cAMP and cGMP signaling cascades. PET studies using 
[11C]IMA107, a biomarker of PDE10A in-vivo, have demonstrated reduced striatal levels of 
PDE10A which correlated with PD duration and disease burden scores such as motor disability 
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and severity of LIDs,34 thus confirming the complex interaction of dopaminergic and non-
dopaminergic mechanisms underlying the pathophysiology of PD.   
Consistent with this observation, voxel-based mapping of cerebral blood flow and metabolic 
activity has also revealed stereotyped, spatially distributed disturbances of regional brain 
function in PD patients. Functional brain imaging with [18F]-fluorodeoxyglucose (FDG) PET has 
provided a means of detecting and quantifying highly specific spatial covariance patterns 
associated with a variety of neurodegenerative disorders including PD.35 The PD-related 
metabolic pattern (PDRP), identified in resting state metabolic imaging data analyzed using 
spatial covariance mapping, is characterized by increased pallidothalamic and pontine metabolic 
activity, associated with reductions in premotor cortex and parietal association areas. Expression 
values for the PDRP measured in individual subjects correlates significantly with loss of 
presynaptic nigrostriatal dopaminergic integrity, as well as with independent clinical ratings of 
motor dysfunction.36,37 Notably, topographically similar metabolic network abnormalities have 
been recently identified in nonhuman primates with experimental parkinsonism due to systemic 
MPTP exposure.38,39 In a recent blinded surgical trial of gene therapy for PD, the rate of PDRP 
progression measured over one year was not affected by placebo treatment.40 In contrast, 
reductions in PDRP expression have been found consistently during levodopa therapy and STN-
DBS and significantly correlated with clinical improvement.41 This suggests that PDRP can be 
considered a reliable biomarker of treatment response. PDRP expression is also sensitive to 
network changes occurring prior to the appearance of motor symptoms. Expression levels of this 
network have recently been found to be abnormally elevated in the clinically unaffected 
hemisphere of early PD patients and in "preclinical" subjects with REM sleep behavior 
disorder.36,42  
Neuroinflammation is also considered to play an important role in PD. 43, 44, 45 Translocator 
protein 18 kDa (TSPO) has been investigated as a potential biomarker of inflammation. Elevated 
TSPO expression was primarily quantified using [11C](R)PK11195 PET. To date, a few studies 
have investigated neuroinflammation in PD patients using [11C](R)PK11195 PET. While some 
studies have found elevated TSPO binding in the nigro-striatal regions,46-48 others did not support 
these observations.49 These limitations have prompted the development of second-generation 
TSPO radioligands (i.e. [11C]PBR28; [18F]-FEPPA, etc.) which present three patterns of binding 
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affinity based on a genetic polymorphism: low-affinity binders (LABs), mixed-affinity binders 
(MABs) and high-affinity binders (HABs).50 These different genotype binding affinity patterns 
account for some of the large inter-individual variability in the outcome measures50 and can be 
predicted by a single-nucleotide polymorphism (SNP), rs6971 located in the exon 4 of the TSPO 
gene resulting in a nonconservative amino-acid substitution at position 147 from alanine to 
threonine (Ala147Thr) in the fifth transmembrane domain of the TSPO protein. Using these 
second-generation TSPO radioligands (i.e. [18F]-FEPPA), Koshimori et al.,43 while noting a 
significant genotype effect (MABs vs HABs) on the [18F]-FEPPA volume distribution (Vt), did 
not observe any disease effect on differential TSPO binding in the striatum of PD patients. Other 
studies however in individuals with Alzheimer’s disease have shown evidence of significant 
increase in [18F]-FEPPA Vt in HABs but not MABs.51  
 
Mild Cognitive Impairment and Dementia in Parkinson's disease 
Have different imaging biomarkers helped to understand cognitive deterioration ? 
The etiology of cognitive decline in PD is heterogeneous. Imaging biomarker studies of 
cognitive impairment in PD have targeted neurotransmitter systems, pathological protein 
deposits, and glucose metabolic or perfusion changes. Prospective evaluation of glucose 
metabolic changes have shown that incident dementia initially may present as a predominant 
hypometabolic posterior cortical pathology involving the visual association cortex, inferior 
parietal and temporal regions, the posterior cingulum and precuneus in PD.52,53 Subsequent 
progression to dementia is associated with mixed subcortical, including the thalamus and caudate 
nuclei, and widespread cortical changes that involve the anterior cortices as well.52,54 Spatial 
covariance mapping has been particularly useful in providing information regarding the network 
topography that underlies cognitive dysfunction in PD.35 Indeed, this approach has revealed a 
distinct PD cognition-related pattern (PDCP) characterized by metabolic reductions in the medial 
prefrontal, premotor, and parietal association regions, with relative increases in the cerebellar 
vermis and dentate nuclei.  In cross-sectional analyses, increased PDCP expression is associated 
with more severe cognitive impairment. PDCP expression is abnormally elevated even in PD 
patients without evidence of cognitive impairment, and highest in those with dementia.35 Of note, 
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PD subjects whose executive function improved with levodopa administration ("responders”) 
also exhibited concurrent reductions in PDCP expression. By contrast, PD subjects showing no 
cognitive improvement (“non-responders”) exhibited no change in PDCP expression with 
levodopa.55 Both groups, however, exhibited significant levodopa-mediated reductions in PDRP 
expression, underscoring the functional distinction between the cognitive and motor networks. 
These findings together with a recent study on glucose metabolism in groups of patients along 
the spectrum of parkinsonism to dementia (PD, PDD, DLB, AD) support the notion that glucose 
metabolism patterns may reflect more the clinical syndrome than the underlying pathology.56  
An intriguing dual syndrome cognitive hypothesis has been proposed, which posits that the high 
frequency of fronto-striatal executive dysfunction in PD may relate to common dopaminergic 
deficits57,58 and that the development of dementia is associated with more widespread and 
posterior cortical changes secondary to additional pathologies, including cholinergic deficits.59,60 
Although dopaminergic denervation affects specific cognitive functions in PD,58 striatal and 
limbo-frontal dopaminergic changes are present in non-demented PD subjects,58 but their 
presence is not sufficient to explain the full development of dementia in PD.61 In contrast, greater 
cholinergic denervation is shown consistently in PD dementia compared to PD.61,62 These 
observations support a more complex pathophysiological model of interacting dopaminergic 
(Fig. 1) and cholinergic degenerative (Fig. 3, 4) changes producing cognitive dysfunctions in 
PD.63-65 However, imaging studies confirmed as well a significant relationship between in vivo 
measures of elevated cortical and, in particular, striatal b- amyloid deposits (measured with 
[11C]PIB) and greater cognitive impairment in PD.66,67 However, the risk of having an abnormal 
[11C] PIB PET study in PD with dementia substantially underestimated the risk of abnormal b-
deposition in the brain at autopsy in people with PD and dementia.68,69 Interestingly, b-amyloid 
deposition measured either in vivo with [11C] PIB or at autopsy with immunohistochemistry did 
not necessarily reflect co-existing AD, since those with dementia due to AD would present 
marked pathologic deposition of both b-amyloid and tau.  Furthermore, the distribution of b-
amyloid measured with [11C] PIB in PDD has a significantly different pattern in the brain 
demonstrated by principal components analysis compared to those with AD.70 Together these 
data indicate the relevance of b-amyloid brain deposition in PD but suggests that this does not 
merely reflect the full spectrum of AD pathology.  
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All of these data demonstrate that neurotransmitter and proteinopathy changes have independent 
and incremental contributions to the cognitive syndrome in PD.65 However, other factors (i.e. 
neuroinflammation) may also play a role. In fact, it has been shown that there may exist a direct 
relationship between b-amyloid load and levels of microglial activation in PD dementia 
subjects,71 suggesting that neuroinflammation may be an early phenomenon, before the dementia 
onset, and that amyloid along with microglial activation could together contribute not only to the 
local neuronal dysfunction, but also to the more remote neuronal disconnection.71 Thus for future 
studies, there is a need for new ligands for not only neurotransmission, in particular 
norepinephrine, but also new neuroinflammatory (besides TSPO binding tracers) and 
proteinopathy targets, especially tracers to visualize neurofibrillary tau and a-synuclein protein 
aggregates for more comprehensive understanding of the cognitive impairment syndrome in PD.  
 
Behavioral and Affective Complications in Parkinson's disease 
What molecular imaging has taught us about behavioral spectrum disorders  
There is evidence of a behavioral spectrum disorder ranging from hypo-dopaminergic levels 
responsible for apathy, anxiety, and depression as described in the withdrawal dopaminergic 
syndrome to hyper-dopaminergic syndrome including impulse control disorders (ICDs), 
hallucinations and psychosis.72,73  Often depression may manifest before the diagnosis of PD, 
however there is considerable evidence suggesting that this complication can be associated with 
a more widespread neurodegenerative process. Imaging reports seem to suggest involvement of 
both dopaminergic and serotonergic systems. While studies using the dopamine transporter 
radioligand (i.e. TRODAT-1) found significantly higher DAT density in the striatum of 
depressed PD patients,74 other investigations with serotonin transporter (i.e. [11C]DASB)	 showed 
abnormal serotonergic neurotransmission in the raphe nuclei and limbic structures which 
correlated with depression measures.75 The serotonergic alteration in depression was confirmed 
by another PET study using 18F-MPPF, a selective serotonin 1A receptor antagonist.76 Apathy 
may also occur in up to 40% of PD patients and, although clinically distinct from depression, the 
two are often comorbid.72 Anatomical and imaging reports have provided evidence that network 
abnormalities within the prefrontal–striatal circuit can lead to an apathetic behavior. Classically, 
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apathy is the result of a disruption of 'emotional-affective' mechanisms linked to the ventral 
striatum, ventromedial prefrontal cortex (PFC) and amygdala.77  PET studies with D2/D3 
receptor antagonist, [11C]-raclopride, have shown several differences in dopaminergic binding 
and transmission in the mesocorticolimbic system between apathetic and non-apathetic PD 
patients.78 [11C]-raclopride binding potential was increased in apathetic PD patients in the 
orbitofrontal cortex (OFC), cingulate cortex, dorsolateral prefrontal cortex (DLPFC), amygdala 
as well as in the striatum, implying either (reactive) increase in D2/D3 receptor expression 
and/or reduction in endogenous synaptic dopamine. Other PET studies with [11C]RTI-32, a 
ligand with affinity to both dopamine and noradrenaline transporters, confirmed that the degree 
of apathy severity was inversely correlated with [11C]RTI-32 binding in the ventral striatum.79 
Taken together, these observations seem to suggest that apathy in PD may result from severe 
dopamine abnormalities in the mesocorticolimbic system, leading to an impaired emotion 
reactivity and poor decision-making processes,77 as also demonstrated in nonhuman primate 
studies of apathetic behaviors after MPTP.80,81 However, from more recent evidence, the 
mechanism of apathy, depression and anxiety in PD may be more complex and may differ 
according to the stage of the disease. In fact, in de novo PD, serotonergic rather than 
dopaminergic degeneration appears to play a significant role in this non-motor triad.82 
While certain behavioral complications are often inherent to the disease process, others are 
mainly associated with symptomatic treatments. Dopamine agonists for example have been 
implicated in the development of impulse control disorders (ICDs).83 Susceptibility to these 
behavioral addictions is associated with increased striatal dopamine release84-86 and reduced 
DAT binding in the ventral striatum.87 While abnormalities in dopaminergic processing in the 
ventral striatum are critical for the development of ICDs, prefrontal mechanisms may also play 
an important inhibitory role in these behaviors.  Activation PET studies with H2[15O] before and 
after administration of a dopamine agonist in PD with and without gambling behavior found 
changes in brain areas implicated in impulse control and response inhibition (lateral orbitofrontal 
cortex, rostral cingulate zone, amygdala).88 Although the agonist significantly increased regional 
cerebral blood flow (rCBF) in these areas in healthy subjects, gamblers showed, in contrast, a 
significant reduction of activity. A subsequent PET study using the extrastriatal dopamine 
receptor ligand [11C]FLB-45789 found significant abnormalities in D2 receptor binding in the 
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OFC and anterior cingulate cortex (ACC) in PD patients with PG, thus confirming the role of 
prefrontal control in the development of ICDs. Similarly, [18F]fluorodopa PET has shown 
abnormalities in the OFC of PD patients with ICDs.90 In PD patients, deep brain stimulation of 
the subthalamic nucleus (STN-DBS) may also contribute to certain impulsive behavior 
associated with high-conflict decisions.91,92 A regional cerebral blood flow study with H2[15O] 
PET during a Go/NoGo task showed a relationship between motor improvement and response 
inhibition. In particular, STN-DBS affected response inhibition, as revealed by an increase in 
commission errors in NoGo trials91 and stop signal task.92 These behavioral changes were 
accompanied by changes in synaptic activity characterized by a reduced activation in the cortical 
networks associated with proactive and reactive response inhibition. These observations suggest 
that modulation of STN with DBS, although it improves motor functions, may tend in parallel to 
favor the appearance of certain impulsive behaviors by acting on mechanisms involved in 
response initiation and/or selection.91 However, to date, the impact of DBS (and its interaction 
with dopamine agonist reduction) on the development of ICD is unclear and still quite 
controversial, as studies using different approaches have shown conflicting results.93-95 
Fatigue is a common non-motor symptom in PD. Recent studies have reported that PD patients 
with higher level of fatigue may show anti-correlated metabolic changes in cortical regions 
associated with the salience (i.e., right insular region) and default (i.e., bilateral posterior 
cingulate cortex) networks.96 Other studies of dopaminergic and serotoninergic function in PD 
patients with and without fatigue demonstrated a serotoninergic denervation in the basal ganglia 
and related limbic circuits.97 PD patients with fatigue had significantly lower SERT binding than 
patients without fatigue in the basal ganglia structure.97 Additionally, voxel-based analysis 
identified reduced dopaminergic activity in caudate and insula, and further SERT reductions in 
cingulate and amygdala in the fatigue group. All together these findings provide the rationale for 
treatment strategies aiming to increase brain level of serotonin and serotoninergic transmission as 
potential treatment of this common complication in PD patients.   
 
 Differentiating atypical Parkinsonisms from PD  
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Is molecular imaging helping us?   
To date most molecular imaging studies in parkinsonism have focused on investigating either 
dopaminergic changes or cerebral blood flow and metabolism. Progressive Supranuclear Palsy 
(PSP) and Corticobasal Syndrome (CBS) are common forms of atypical parkinsonism (APS), 
and in early stages, can be sometimes quite difficult to diagnose as they can overlap clinically 
with PD, and other parkinsonian syndromes including multiple system atrophy (MSA). Previous 
imaging studies have reported in CBS either asymmetric hypoperfusion or reduced metabolism 
mainly in the striatum as well as parietal and frontal cortex contralateral to the affected limb.98 
CBS may also be variably associated with asymmetric striatal dopamine denervation (e.g. 99). 
Similarly, PSP patients may present with a variable pattern of hypometabolism in the fronto-
striatal-thalamic regions depending on the clinical presentation and progression.98,100 Families 
with mutations in the progranulin gene presented profound imaging changes of asymmetric 
hypoperfusion on SPECT and parietal atrophy.101,102 Subsequent work in CBS identified that 
hypoperfusion within the left inferior parietal lobule, including the left angular gyrus was 
associated with more severe ideomotor apraxia. Voxel-based spatial covariance mapping has also 
been used to identify disease-specific networks for MSA, PSP, and CBD.103,104 Importantly, an 
automated logistic regression algorithm based on pattern expression values has been developed 
to aid in discriminating individuals with idiopathic PD from those with atypical parkinsonian 
syndromes, and in differentiating among the various forms of APS. This approach had excellent 
diagnostic specificity in an original data set105 and in a subsequent validation sample.106 Other 
methods such as relevance vector machine analysis have also been used for single case 
classification with promising results.107,108 Prospective validation studies are needed before the 
relative utility of these methods can be determined. Neuroinflammation may play an important 
role in various atypical parkinsonisms. To date, only a few studies have investigated 
neuroinflammation in these disorders using mainly first generation of radiotracers, i.e. 
[11C](R)PK11195.109 While the findings are highly suggestive, they require further confirmation.  
Other studies assessed the diagnostic value of dopaminergic tracers using (18F)-FP-CIT PET in 
differentiating PSP and MSA from PD.110 Compared to PD, PSP and MSA have more prominent 
dopamine transporter loss in the anterior caudate and ventral putamen, respectively. However, it 
should be emphasized that the pattern of presynaptic dopaminergic impairment is not felt to 
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reliably differentiate among various neurodegenerative forms of parkinsonism. Studies in which 
presynaptic dopamine markers are combined with measures of postsynaptic dopamine receptors 
may help differentiate PD from atypical parkinsonian syndromes, but not between these various 
syndromes. Except in a few highly specialized centers, neuroimaging has had a very limited 
diagnostic value in the differential diagnosis of PSP, CBS and other tauopathies. For this reason, 
the development of PET radiotracers specific for tau represents one of the most active and 
challenging areas in molecular imaging.  
Several groups have recently reported encouraging results toward the development of selective 
tau imaging agents.111,112 [18F]T807 (also known as [18F]-AV-1451) has been reported having 
excellent selectivity for paired helical filaments of tau.111,112 This tracer demonstrated high-
affinity and selectivity as well as favorable in-vivo properties, making this a potentially 
promising candidate as an imaging agent for tau.111 Another tracer, [11C]PBB3, has also been 
recently applied to human studies, providing PET demonstration of spreading tau pathologies in 
transition from normal aging to advanced Alzheimer’s disease.113 PET imaging of sporadic 4-
repeat tau pathologies in PSP and CBD is currently being conducted, and preliminary data have 
indicated an increased retention of [11C]PBB3 in multiple brain areas, including white matter, in 
patients with these disorders relative to age-matched controls. Studies of in-vitro binding assays 
using brain homogenates found that the two tau probes, PBB3 and T807, do not compete with 
each other for binding sites in PSP tau aggregates. Other investigations with [18F]-AV-1451 (i.e. 
[18F]T807) in PSP and CBS have shown preliminary findings with either increase114 or no 
retention.115  
Future directions of molecular imaging: need for harmonization and multi-
center collaboration  
Exciting new tracer developments hold the potential for in vivo markers of underlying pathology, 
which is of particular interest for interventions directly targeting protein aggregation. However, 
with increasingly diverse and sophisticated imaging approaches, it is now becoming more 
problematic than ever for non-experts to assess the validity and significance of new studies. The 
scientific community should therefore move toward common standards and harmonization in 
molecular imaging. Good scientific practice criteria including sample size, correction for 
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multiple comparisons, correction for the effects of age, motion, and partial volume effects are 
among the most important issues to address. Anticipating excessive use of the term “biomarker” 
in imaging studies, we propose to use standardized terminology, which may help in the design 
future experiments, especially when looking for surrogate markers in interventional studies. In 
line with the FDA/NIH BEST Resource (2016) propositions, a biomarker is a defined as a 
characteristic that is measured as an indicator of a biological (pathogenic) process. A diagnostic 
biomarker should increase diagnostic accuracy for pathological or clinical entities in comparison 
to clinical judgment alone. In agreement with this definition, certain imaging characteristics may 
also serve to enrich specific features in a trial population (for example as a target verification tool 
in case of tau PET). Monitoring biomarkers are measured serially and used to detect a change in 
the degree or extent of disease.  This kind of imaging characteristic may serve as a biomarker 
that may predict clinical efficacy but not likely to act as a surrogate endpoint since such an 
imaging biomarker would not reflect unintended side effects. For PD, most valuable biomarkers 
would certainly be prodromal diagnostic biomarkers and monitoring biomarkers for disease 
progression at early/prodromal stages. For atypical parkinsonism, there often is a mismatch 
between clinical and pathological entities (e.g. CBS with AD pathology, PSP pathology with 
different clinical phenotypes).116,117 Therefore, diagnostic biomarkers in atypical parkinsonism 
should not be regarded as diagnostic for a clinical entity, unless the biomarker is pathologically 
validated. While certainly fruitful, this kind of endeavor only seems feasible in a large multi-
center studies strategically focusing on the integration of postmortem information. 
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Figure Legends 
 
Figure 1 depicts the ascending nigrostriatal (red), mesolimbic (green), and mesocortical (blue) 
dopaminergic pathways.  
 
Figure 2 shows dopaminergic nerve terminal and various PET radiotracers for the assessment of 
its integrity.  
 
Figure 3 (top) depicts the distribution of the serotonergic pathways (Yellow), (bottom) depicts 
the distribution of the cholinergic pathway (Red).  
 
Figure 4 shows cholinergic (left) and serotonergic (right) nerve terminal and various PET 
radiotracers for the assessment of their integrity.  
